Autoantibody profiles and their association with blood eosinophils in asthma and COPD

Tamai, Ken; Yoshimatsu, Harukazu; Saito, Toshiharu; Matsuoka, Hiroaki; Okada, Nobuhiko; Koma, Yasuko; Otsuka, Akiko; Oda, Nao; Inoue, Shuichiro; Kume, Shinji; Suzuki, Yujiro

doi:10.1016/j.alit.2016.08.005

Cited by 8 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 28 The latter study, however, showed that ANAs were predictors of asthma exacerbations, mortality and decrease in lung function. In contrast, the study by Tamai and co-workers 27 reported no correlation with clinical indices of severe asthma in patients who showed ANAs at clinically relevant titers of 1:160.…”

Section: Autoimmune Phenomena In Asthma: Evidence From Immunological mentioning

confidence: 84%

“…However, another study reported that clinically significant high ANA titers ≥1:160 was detected in 10% of patients with asthma but there was no significant association between ANA positivity and clinical indices of asthma severity. 27 There were conflicting reports of clinical signs of ANAs between these studies. While signs of autoimmune manifestations such as rheumatic symptoms, cold sensitivity and Raynaud's phenomenon were reported in patients with low titer 1:40, 26 while the study with patients with higher ANA titers (>1:100) reported otherwise.…”

Section: Autoimmune Phenomena In Asthma: Evidence From Immunological mentioning

confidence: 99%

See 1 more Smart Citation

Autoimmune Responses in Severe Asthma

Mukherjee

Nair

2018

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

Asthma and autoimmune diseases both result from a dysregulated immune system, and have been conventionally considered to have mutually exclusive pathogenesis. Autoimmunity is believed to be an exaggerated Th1 response, while asthma with a Th2 underpinning is congruent with the well-accepted Th1/Th2 paradigm. The hypothesis of autoimmune involvement in asthma has received much recent interest, particularly in the adult late-onset non-atopic patients (the “intrinsic asthma”). Over the past decades, circulating autoantibodies against diverse self-targets (beta-2-adrenergic receptors, epithelial antigens, nuclear antigens, etc.) have been reported and subsequently dismissed to be epiphenomena resulting from a chronic inflammatory condition, primarily due to lack of evidence of causality/pathomechanism. Recent evidence of ‘granulomas’ in the lung biopsies of severe asthmatics, detection of pathogenic sputum autoantibodies against autologous eosinophil proteins (e.g., eosinophil peroxidase) and inadequate response to monoclonal antibody therapies (e.g., subcutaneous mepolizumab) in patients with evidence of airway autoantibodies suggest that the role of autoimmune mechanisms be revisited. In this review, we have gathered available reports of autoimmune responses in the lungs, reviewed the evidence in the context of immunogenic tissue-response and danger-associated molecular patterns, and constructed the possibility of an autoimmune-associated pathomechanism that may contribute to the severity of asthma.

show abstract

Section: Autoimmune Phenomena In Asthma: Evidence From Immunological mentioning

confidence: 84%

Section: Autoimmune Phenomena In Asthma: Evidence From Immunological mentioning

confidence: 99%

Autoimmune Responses in Severe Asthma

Mukherjee

Nair

2018

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

show abstract

“…Autoantibodies (Abs) are a hallmark of autoimmunity. Increased levels of Abs have been detected in most autoimmune disorders 7. In asthmatic patients, especially non-allergic asthmatics, several elevated serum Abs (Se-Abs) against bronchial tissue antigens and nuclear antigens have been detected, which further provides evidence that the cause of asthma may be related to autoimmune dysregulation 8910111213141516…”

Section: Introductionmentioning

confidence: 93%

“…We conducted a prospective study to measure 10 types of Abs in matched Sp and Se samples and further compared and analyzed their associations with clinical characteristics. Our selected Abs—Ab against proteinase-3 (anti-PR3), Ab against La/Sjögren syndrome type B antigen (anti-SSB), Ab against Ro/Sjögren syndrome type A antigen (anti-SSA), Ab against Smith antigen (anti-Sm), Ab against ribosomal phosphoprotein P0 (anti-P0), Ab against DNA topoisomerase (anti-Scl-70), Ab against histidyl-tRNA synthetase (anti-Jo1), Ab against U1 small nuclear ribonucleoprotein (anti-U1-SnRNP), Ab against myeloperoxidase (anti-MPO) and Ab against thyroid peroxidase (anti-TPO)—have been examined in previous research aiming to explore the relationship between asthma and autoimmune disease716 or commonly present in autoimmune diseases 19…”

Section: Introductionmentioning

confidence: 99%

Sputum Autoantibodies Are More Relevant in Autoimmune Responses in Asthma than Are Serum Autoantibodies

Qin

Long

Xiao

et al. 2019

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

Purpose The data on the differences between sputum autoantibodies (Sp-Abs) and serum autoantibodies (Se-Abs) in reflection of autoimmune responses to lungs is still lacking. Methods Ten types of Abs were investigated in matched Se and Sp samples collected from recruited subjects. Correlations between Ab levels and airway inflammatory parameters and measures of pulmonary function were assessed. The network-based and inter-correlated analysis was performed to explore the patterns of Sp- and Se-Ab profiles. Results Fifty stable asthmatic patients and 24 healthy volunteers were recruited for our study, 15 with mild asthma, 18 with moderate asthma and 17 with severe asthma. The concentrations of Sp-Ab against U1 small nuclear ribonucleoprotein (Sp-anti-U1-SnRNP), Sp-Ab against Smith antigen and Se-Ab against thyroid peroxidase (anti-TPO) in severe asthmatics and Sp-anti-U1-SnRNP in moderate asthmatics were significantly higher compared to healthy controls and mild asthmatic subjects ( P < 0.05). Sp-anti-U1-SnRNP levels were positively correlated with the dose of inhaled corticosteroids, Sp eosinophil counts and fractional exhaled nitric oxide ( r = 0.326, P = 0.022; r = 0.356, P = 0.012; r = 0.241, P = 0.025, respectively) and negatively correlated with Sp neutrophil counts ( r = −0.308, P = 0.031) with adjustment for age. Spearman's correlation matrix showed multiple inter-correlations among Sp-Abs and Se-Abs ( P < 0.05) while only the levels of Ab against DNA topoisomerase and anti-TPO in Se were correlated with those Sp-Ab counterparts ( P < 0.05). The network-based analysis defined 2 clusters: clusters 1 and 2 contained 10 Sp-Abs and 10 Se-Abs, respectively. Conclusions This study observes that Sp-Abs are more associated with clinical parameters and the severity of disease in asthma compared to Se-Abs. Targeting on Sp-Abs which are the hallmark of the localized autoimmune event might help us better understand the role of autoimmunity in the pathological mechanism of asthma.

show abstract

“…The role of autoimmunity in chronic airway diseases such as asthma and COPD has obtained attention in recent years (9)(10)(11)(12). Airway inflammation in COPD is heterogeneous in nature and pattern.…”

Section: Introductionmentioning

confidence: 99%

Sputum and serum autoantibody profiles and their clinical correlation patterns in COPD patients with and without eosinophilic airway inflammation

et al. 2020

View full text Add to dashboard Cite

Background: Autoimmunity plays a role in the pathogenesis of chronic obstructive pulmonary disease (COPD). However, the autoantibody responses and their clinical correlation patterns in COPD patients with and without airway eosinophilic inflammation are unknown. The aim of this study was to compare the autoantibody profiles and their clinical associations in stable COPD patients, stratified by airway inflammatory phenotypes.Methods: Matched sputum and serum, obtained from 62 stable COPD patients and 14 age-matched controls, were assayed for the presence of IgG and IgM antibodies against 13 autoantigens using protein array. A sputum eosinophil count ≥3% was used as cut-off value to stratify COPD patients into eosinophilic and non-eosinophilic groups. Correlation network analysis was used to evaluate the correlation patterns among autoantibody and clinical variables in each group. Results: There were no significant differences of clinical parameters and autoantibody levels between the two COPD groups. In non-eosinophilic COPD, sputum anti-CytochromeC_IgG and anti-Aggrecan_IgM were significantly higher than those in healthy controls, and prior exacerbation was positively associated with lung function and sputum anti-Collagen-IV_IgG. While in eosinophilic COPD, sputum/serum anti-heat shock protein (HSP)47_IgG, serum anti-HSP70_IgG and serum anti-Amyloid-beta_IgG were significantly lower than those in healthy controls, and no significant correlation between prior exacerbations and lung function was found. Differences were also observed in network hubs, with the network for non-eosinophilic COPD possessing 9 hubs comprising two lung function parameters and seven autoantibodies, compared with eosinophilic COPD possessing 12 hubs all comprising autoantibodies. Conclusions: Autoantibody responses were heterogeneous and differentially correlated with the exacerbation risk and other clinical parameters in COPD patients of different inflammatory phenotypes. These findings provide useful insight into the need for personalized management for preventing COPD exacerbations. 3086 Liang et al. Sputum and serum autoantibody profiles in eosinophilic COPD

show abstract

Autoantibody profiles and their association with blood eosinophils in asthma and COPD

Cited by 8 publications

References 26 publications

Autoimmune Responses in Severe Asthma

Autoimmune Responses in Severe Asthma

Sputum Autoantibodies Are More Relevant in Autoimmune Responses in Asthma than Are Serum Autoantibodies

Sputum and serum autoantibody profiles and their clinical correlation patterns in COPD patients with and without eosinophilic airway inflammation

Contact Info

Product

Resources

About